Osteoprotegerin genetic polymorphisms and age of symptom onset in ankylosing spondylitis

Rheumatology

Volumn 50, Issue 2, 2011, Pages 359-365

  Huang, Chun Huang ^a   Wei, James Cheng Chung ^a,b,c   Hung, Pei Shan ^b   Shiu, Li Jie ^b   Tsay, Ming Dow ^a   Wong, Ruey Hong ^b,c   Lee, Hong Shen ^b,c  

^a TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Age of symptom onset; Ankylosing spondylitis; Osteoprotegerin; Polymorphism

Indexed keywords

HLA B27 ANTIGEN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ADULT; ALLELE; ANKYLOSING SPONDYLITIS; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT;

ADULT; AGE OF ONSET; BONE RESORPTION; CASE-CONTROL STUDIES; FEMALE; HLA-B27 ANTIGEN; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPROTEGERIN; POLYMORPHISM, GENETIC; RANK LIGAND; SPONDYLITIS, ANKYLOSING;

EID: 78751691256     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq306     Document Type: Article

References (41)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369:1379-90.
2. Calin A, Brophy S, Blake D. Impact of sex on inheritance of ankylosing spondylitis: a cohort study. Lancet 1999;354: 1687-90.
3. Brewerton DA, Hart FD, Nicholls A et al. Ankylosing spondylitis and HL-A 27. Lancet 1973;1:904-7.
4. Khan MA, Ball EJ. Genetic aspects of ankylosing spondylitis. Best Pract Res Clin Rheumatol 2002;16: 675-90.
5. Ralston SH, Urquhart GD, Brzeski M et al. Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. Br Med J 1990;300:563-5.
6. Donnelly S, Doyle DV, Denton A et al. Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 1994;53:117-21.
7. Hadjidakis DJ. Androulakis II. Bone remodeling. Ann N Y Acad Sci 2006;1092:385-96.
8. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007;9(Suppl. 1):S1.
9. Yasuda H, Shima N, Nakagawa N et al. A novel molecular mechanism modulating osteoclast differentiation and function. Bone 1999;25:109-13.
10. Hsu H, Lacey DL, Dunstan CR et al..Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 96:3540-5.
11. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
12. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
13. Burgess TL, Qian Y, Kaufman S et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999;145:527-38.
14. Akatsu T, Murakami T, Nishikawa M et al. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem Biophys Res Commun 1998;250:229-34.
15. Mizuno A, Amizuka N, Irie K et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998; 247:610-5.
16. Wong BR, Rho J, Arron J et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272: 25190-4.
17. Mencej S, Prezelj J, Kocijancic A et al. Association of TNFSF11 gene promoter polymorphisms with bone mineral density in postmenopausal women. Maturitas 2006;55:219-26.
18. Hsu YH, Niu T, Terwedow HA et al. Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. Hum Genet 2006;118:568-77.
19. Wuyts W, Van Wesenbeeck L, Morales-Piga A et al. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone 2001;28:104-7.
20. Morinaga T, Nakagawa N, Yasuda H et al. Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. Eur J Biochem 1998;254:685-91.
21. Zhao HY, Liu JM, Ning G et al. The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women. Osteoporos Int 2005;16:1519-24.
22. Langdahl BL, Carstens M, Stenkjaer L et al. Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. J Bone Miner Res 2002;17:1245-55.
23. Hamersma J, Cardon LR, Bradbury L et al. Is disease severity in ankylosing spondylitis genetically determined? Arthritis Rheum 2001;44:1396-400.
24. Porcher R, Said-Nahal R, D'Agostino MA et al. Two major spondylarthropathy phenotypes are distinguished by pattern analysis in multiplex families. Arthritis Rheum 2005;53:263-71.
25. Breban M, Miceli-Richard C, Zinovieva E et al. The genetics of spondyloarthropathies. Joint Bone Spine 2006;73:355-62.
26. Maksymowych WP, Russell AS. Polymorphism in the LMP2 gene influences the relative risk for acute anterior uveitis in unselected patients with ankylosing spondylitis. Clin Invest Med 1995;18:42-6.
27. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
28. Chou CT, Tsai YF, Liu J et al. The detection of the HLA-B27 antigen by immunomagnetic separation and enzyme-linked immunosorbent assay-comparison with a flow cytometric procedure. J Immunol Methods 2001;255: 15-22.
29. Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 2004;31: 2236-41.
30. Chou CT, Tsai YF, Liu J et al. Investigation of the genetic influence of the OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in the Irish population. Calcif Tissue Int 2002;71:26-35.
31. Ueland T, Bollerslev J, Wilson SG et al. No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women. Bone 2007;40:175-81.
32. Brophy S, Calin A. Ankylosing spondylitis: interaction between genes, joints, age at onset, and disease expression. J Rheumatol 2001;28:2283-8.
33. Khan MA, Kushner I, Braun WE. Comparison of clinical features in HLA-B27 positive and negative patients with ankylosing spondylitis. Arthritis Rheum 1977;20: 909-12.
34. Wu Z, Lin Z, Wei Q et al. Clinical features of ankylosing spondylitis may correlate with HLA-B27 polymorphism. Rheumatol Int 2009;29:389-92.
35. Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F. Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine 2007; 74:249-53.
36. MacDonald AG, Birkinshaw G, Durham B et al. Biochemical markers of bone turnover in seronegative spondylarthropathy: relationship to disease activity. Br J Rheumatol 1997;36:50-3.
37. Hofbauer LC, Heufelder AE. The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 2001;44:253-9.
38. Broman P, Bodur H, BingölNet al. Bone mineral density and bone turnover markers in a group of male ankylosing spondylitis patients: relationship to disease activity. J Clin Rheumatol 2001;7:315-21.
39. Bromley M, Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 1984;27:968-75.
40. Vandooren B, Cantaert T, Noordenbos T et al. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum 2008;58:718-29.
41. Kim JG, Kim JH, Kim JY et al. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause 2007;14: 913-8.